PT  - JOURNAL ARTICLE
AU  - Kane, Ari
AU  - Thorpe, Matthew P.
AU  - Morse, Michael A.
AU  - Howard, Brandon A.
AU  - Oldan, Jorge D.
AU  - Zhu, Jason
AU  - Wong, Terence Z.
AU  - Petry, Neil A.
AU  - Reiman, Robert
AU  - Borges-Neto, Salvador
TI  - Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with <sup>131</sup>I-MIBG
AID  - 10.2967/jnumed.117.202150
DP  - 2018 Nov 01
TA  - Journal of Nuclear Medicine
PG  - 1708--1713
VI  - 59
IP  - 11
4099  - http://jnm.snmjournals.org/content/59/11/1708.short
4100  - http://jnm.snmjournals.org/content/59/11/1708.full
SO  - J Nucl Med2018 Nov 01; 59
AB  - This retrospective analysis identifies predictors of survival in a cohort of patients with meta-iodobenzylguanidine (MIBG)–positive stage IV pulmonary and gastroenteropancreatic neuroendocrine tumor (P/GEP-NET) treated with 131I-MIBG therapy, to inform treatment selection and posttreatment monitoring. Methods: Survival, symptoms, imaging, and biochemical response were extracted via chart review from 211 P/GEP-NET patients treated with 131I-MIBG between 1991 and 2014. For patients with CT follow-up (n = 125), imaging response was assessed by RECIST 1.1 if images were available (n = 76) or by chart review of the radiology report if images could not be reviewed (n = 49). Kaplan–Meier analysis and Cox multivariate regression estimated survival and progression-free survival benefits predicted by initial imaging, biochemical response, and symptomatic response. Results: All patients had stage IV disease at the time of treatment. Median survival was 29 mo from the time of treatment. Symptomatic response was seen in 71% of patients, with the median duration of symptomatic relief being 12 mo. Symptomatic response at the first follow-up predicted a survival benefit of 30 mo (P < 0.001). Biochemical response at the first clinical follow-up was seen in 34% of patients, with stability of laboratory values in 48%; response/stability versus progression extended survival by 40 mo (P < 0.03). Imaging response (20% of patients) or stability (60%) at the initial 3-mo follow-up imaging extended survival by 32 mo (P < 0.001). Additionally, multiple 131I-MIBG treatments were associated with 24 mo of additional survival (P < 0.05). Conclusion: Therapeutic 131I-MIBG for metastatic P/GEP-NETs appears to be an effective means of symptom palliation. Imaging, biochemical, and symptomatic follow-up help prognosticate expected survival after 131I-MIBG therapy. Multiple rounds of 131I-MIBG are associated with prolonged survival.